Microscopic view of bladder cancer cells being treated with BCG and Chemohyperthermia.

Is BCG Still the Gold Standard for Bladder Cancer? Weighing the Odds Against Chemohyperthermia

Rhea Morgan monogram
Rhea Morgan in Health & Wellness October 2026 • 4 min read.

"A new study explores whether chemohyperthermia can rival the effectiveness of BCG for high-risk, non-muscle-invasive bladder cancer."


Bladder cancer is a common and serious diagnosis, especially for men. The good news is that if caught early, specifically when it’s non-muscle-invasive bladder cancer (NMIBC), the chances of survival are high – over 90%. The challenge, however, lies in preventing the cancer from recurring after initial treatment.

Following the removal of the tumor through a procedure called transurethral resection (TUR), many patients face a tough reality: the cancer can come back. To combat this, doctors often recommend adjuvant intravesical therapy, where medication is placed directly into the bladder to reduce the risk of recurrence and progression. The European Association of Urology (EAU) supports this approach, with one of the mainstays of treatment being the Bacillus Calmette-Guérin, more commonly known as BCG.

BCG has been a go-to treatment, but it's not without its drawbacks. The side effects can be difficult, leading researchers to explore new options. One such alternative is chemohyperthermia (C-HT), which combines chemotherapy with heat to target cancer cells. While promising, there has been a lack of direct comparisons between BCG and C-HT – until now. A recent study has taken on the challenge of comparing these two treatments, offering valuable insights for those navigating bladder cancer treatment options.

AI Search Multiple angles on this topic

BCG and Bladder Cancer Outcomes

Bacillus Calmette-Guérin (BCG) is described as the standard immune therapy for non-muscle-invasive bladder cancer. One source reports that overall bladder cancer five-year survival is about 77.9%, while also presenting survival by stage and BCG success rates for non-muscle-invasive disease. Another report highlights that many patients with recurrent non-muscle-invasive disease were managed without bladder removal, often through additional in-bladder treatments and close follow-up.

BCG vs. Chemohyperthermia: A Head-to-Head Comparison

Microscopic view of bladder cancer cells being treated with BCG and Chemohyperthermia.

Researchers conducted a retrospective study analyzing data from 1,937 patients diagnosed with bladder cancer between January 2004 and January 2014. The goal was to compare how well C-HT and BCG prevent cancer recurrence. Patients treated with C-HT were carefully matched with those treated with BCG, ensuring a fair comparison. Statistical models were then used to determine the link between the treatments and the likelihood of recurrence or progression.

Out of the 710 patients who received intravesical treatments, a select group was chosen for the C-HT (40 patients) and BCG (142 patients) groups. After matching patient characteristics, the study revealed some key differences:

  • The two-year recurrence-free interval was 76.2% in the C-HT group compared to 93.9% in the BCG group.
  • Treatment with C-HT was linked to a higher risk of tumor recurrence.
  • High-grade tumors were also associated with an increased risk of recurrence.
  • However, in more complex analysis, C-HT didn't show a statistically significant difference from BCG in terms of recurrence risk.
  • There were no significant differences in progression rates between C-HT and BCG.
AI Search Multiple angles on this topic

BCG Research and Emerging Options

Recent reviews continue to describe intravesical BCG immunotherapy as the gold standard adjuvant treatment for high-risk and selected intermediate-risk non-muscle-invasive bladder cancer. At the same time, a global BCG shortage lasting two decades and the limited options for patients with BCG-refractory or relapsing disease have driven testing of new therapeutic strategies. A 2025 review also examines BCG's direct antitumor effects, its interactions with bladder tumor microenvironment cell types, and its relationship with the bladder microbiome.

Evidence Still Needs Confirmation

The European Association of Urology guideline material states that the cited data need to be corroborated by further studies. This signals that the evidence discussed in this section should not be treated as conclusive on its own. Further research is therefore needed before those findings can be considered firmly established.

The results suggest that C-HT may not be as effective as BCG in preventing recurrence in BCG-naive, high-risk NMIBC patients. While BCG significantly improved the recurrence-free interval, C-HT did not achieve the same level of success.

The Bottom Line: BCG Still Reigns, But the Search Continues

This study indicates that for patients with high-risk NMIBC who haven't been treated with BCG before, BCG remains the more effective option. While C-HT shows promise, more research is needed to refine its application and determine its potential role in bladder cancer treatment. As the quest for better treatments continues, it’s vital for patients to discuss all options with their healthcare team to make informed decisions based on their individual needs and circumstances.

AI Search Multiple angles on this topic

BCG's Long Clinical Legacy

A historical review describes BCG as the most important tuberculosis vaccine 100 years after its first use. The same review reports that, over the past four decades, BCG has become the most widely accepted and effective drug used to treat aggressive localized bladder cancer. It chronicles the narrow path from tuberculosis prevention to approval and worldwide acceptance of BCG immunotherapy for bladder cancer.

Chemohyperthermia and BCG at 24-36 months

  • 29.5% vs 37.4% recurrence rateRecurrence rates were 29.5% with chemohyperthermia and 37.4% with BCG, a relative estimate that did not establish a significant difference between treatments.[1]Caveat: No significant difference; RR 0.83, 95% CI 0.61–1.13.
  • 4.4% vs 7.6% progression rateProgression rates were 4.4% with chemohyperthermia and 7.6% with BCG; the comparison likewise found no significant difference.[1]Caveat: No significant difference; RR 0.62, 95% CI 0.26–1.49.

What the comparisons do and do not show

In these comparisons, the observed recurrence and progression rates were numerically lower with chemohyperthermia, but the evidence did not establish that either treatment had a different rate from the other. The estimates therefore do not show that chemohyperthermia is superior, or that the treatments are equivalent.[1]

How trial designs shape the comparison

A randomized pilot trial compared HIVEC with BCG in high-risk disease, but its convenient sample of 50 patients was selected to inform future, larger randomized trials. Its results are therefore an early comparison, not a definitive answer.[2]

Another randomized comparison closed early and was underpowered; treatment blinding was not possible, leaving potential for bias. These design constraints make its treatment comparison less conclusive.[3]

In HIVEC-II, 41% of patients assigned to chemohyperthermia did not complete treatment according to protocol, most commonly because of equipment issues. Incomplete delivery makes it harder to separate how well the treatment works from whether it could be delivered as planned.[4]

BCG is described as effective at reducing recurrence and progression in intermediate- and high-risk NMIBC, while severe global supply shortages have prompted efforts to identify alternatives. Together, these facts explain why heated chemotherapy is being compared with BCG, without establishing that it can replace it.[1] [2]

Questions for the next comparisons

  • Would a larger randomized comparison produce clearer estimates of HIVEC’s effects, given that the pilot trial was designed to inform larger trials?[2]
  • How much would the results of the prematurely closed trial change with adequate statistical power and blinded treatment assessment, which was not possible in that trial?[3]

Sources

  1. Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis - PMC Lock (pmc.ncbi.nlm.nih.gov)
  2. Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial (pmc.ncbi.nlm.nih.gov)
  3. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk N (pubmed.ncbi.nlm.nih.gov)
  4. Adjuvant intravesical chemohyperthermia or conventional chemotherapy in an era of bacillus Calmette-Guérin shortage for non-muscle invasive bladder cancer: The HIVEC-II trial (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What exactly is BCG treatment for bladder cancer?

BCG, or Bacillus Calmette-Guérin, is a type of intravesical therapy used to treat high-risk, non-muscle-invasive bladder cancer (NMIBC) after a transurethral resection (TUR). It involves placing medication directly into the bladder to reduce the risk of the cancer returning. BCG has been a standard treatment for many years, recommended by organizations like the European Association of Urology (EAU), due to its effectiveness in preventing recurrence. However, it can cause side effects, which has led to the exploration of alternative treatments.

2

What is chemohyperthermia, and why is it being considered for bladder cancer?

Chemohyperthermia (C-HT) is an alternative treatment for bladder cancer that combines chemotherapy with heat to target cancer cells. It's being investigated as a potential option for patients with high-risk NMIBC. The significance of C-HT lies in the possibility of offering a different approach for patients who may not be suitable for BCG or for whom BCG is not effective. While promising, studies are ongoing to determine its effectiveness compared to BCG.

3

What is transurethral resection (TUR), and why is it mentioned in the context of bladder cancer treatment?

Transurethral resection (TUR) is a surgical procedure used to remove tumors in the bladder. It is typically the first step in treating non-muscle-invasive bladder cancer (NMIBC). After TUR, adjuvant intravesical therapy, such as BCG or chemohyperthermia, is often recommended to reduce the risk of the cancer recurring. TUR plays a critical role in initially addressing the tumor and setting the stage for further treatment to prevent recurrence.

4

What does adjuvant intravesical therapy mean in the treatment of bladder cancer, and why is it important?

Adjuvant intravesical therapy involves placing medication directly into the bladder after a transurethral resection (TUR) to prevent bladder cancer from recurring. Both BCG and chemohyperthermia (C-HT) fall under this category. This type of therapy is important because, after the initial tumor removal, there's a significant risk of recurrence, especially in high-risk cases. Intravesical therapy aims to target any remaining cancer cells in the bladder, reducing the likelihood of the cancer coming back or progressing to a more advanced stage.

5

What were the main findings of the study comparing chemohyperthermia and BCG treatments?

The study compared chemohyperthermia (C-HT) and BCG in preventing recurrence in patients with high-risk, non-muscle-invasive bladder cancer (NMIBC). The results indicated that BCG was more effective than C-HT in preventing recurrence. Specifically, the two-year recurrence-free interval was higher in the BCG group. While C-HT showed promise, it did not achieve the same level of success as BCG in this study. This suggests that, for patients who haven't been treated with BCG before, BCG remains the preferred option. Further research is needed to refine the application of C-HT and determine its potential role in bladder cancer treatment.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.